Search research articles
Contact Us
Filters
Showing results (51-60 of 78) with videos related to
Page
of 8
Sort By:
Medicine
|
November 9, 2018
Effects of Shuganjianpihuatanxingqi decoction on mild subclinical hypothyroidism: A SPIRIT compliant randomized controlled trial study protocol
Litao Bai, Jing Zhao, Jialiang Gao, et al.
JCI Insight
|
October 17, 2023
Dormant tumors circumvent tumor-specific adaptive immunity by establishing a Treg-dominated niche via DKK3
Timothy N Trotter, Carina E Dagotto, Delila Serra, et al.
Journal for Immunotherapy of Cancer
|
June 14, 2020
HER2-LAMP vaccines effectively traffic to endolysosomal compartments and generate enhanced polyfunctional T cell responses that induce complete tumor regression
Alan Chen Chen, Renhuan Xu, Tao Wang, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy
|
January 29, 2009
Transient pretreatment with glucocorticoid ablates innate toxicity of systemically delivered adenoviral vectors without reducing efficacy
Sergey S Seregin, Daniel M Appledorn, Aaron J McBride, et al.
Blood
|
September 24, 2011
Inhibition of Rac GTPase signaling and downstream prosurvival Bcl-2 proteins as combination targeted therapy in MLL-AF9 leukemia
Benjamin Mizukawa, Junping Wei, Mahesh Shrestha, et al.
Cancer Cell
|
June 10, 2008
Microenvironment determines lineage fate in a human model of MLL-AF9 leukemia
Junping Wei, Mark Wunderlich, Catherine Fox, et al.
Vaccines
|
November 26, 2024
Vaccination Against Androgen Receptor Splice Variants to Immunologically Target Prostate Cancer
Robert D Marek, Selena Halabi, Mu-En Wang, et al.
Breast Cancer Research : BCR
|
August 11, 2018
Polyfunctional anti-human epidermal growth factor receptor 3 (anti-HER3) antibodies induced by HER3 vaccines have multiple mechanisms of antitumor activity against therapy resistant and triple negative breast cancers
Takuya Osada, Zachary C Hartman, Junping Wei, et al.
Oncoimmunology
|
July 7, 2017
Vaccination targeting human HER3 alters the phenotype of infiltrating T cells and responses to immune checkpoint inhibition
Takuya Osada, Michael A Morse, Amy Hobeika, et al.
Journal of Translational Medicine
|
February 14, 2012
Phase 1 clinical trial of HER2-specific immunotherapy with concomitant HER2 kinase inhibition [corrected]
Erika Hamilton, Kimberly Blackwell, Amy C Hobeika, et al.
Page
of 8
Search research articles
Search
Showing results (51-60 of 78) with videos related to
Sort By:
Page
of 8
Medicine
|
November 9, 2018
Effects of Shuganjianpihuatanxingqi decoction on mild subclinical hypothyroidism: A SPIRIT compliant randomized controlled trial study protocol
Litao Bai, Jing Zhao, Jialiang Gao, et al.
JCI Insight
|
October 17, 2023
Dormant tumors circumvent tumor-specific adaptive immunity by establishing a Treg-dominated niche via DKK3
Timothy N Trotter, Carina E Dagotto, Delila Serra, et al.
Journal for Immunotherapy of Cancer
|
June 14, 2020
HER2-LAMP vaccines effectively traffic to endolysosomal compartments and generate enhanced polyfunctional T cell responses that induce complete tumor regression
Alan Chen Chen, Renhuan Xu, Tao Wang, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy
|
January 29, 2009
Transient pretreatment with glucocorticoid ablates innate toxicity of systemically delivered adenoviral vectors without reducing efficacy
Sergey S Seregin, Daniel M Appledorn, Aaron J McBride, et al.
Blood
|
September 24, 2011
Inhibition of Rac GTPase signaling and downstream prosurvival Bcl-2 proteins as combination targeted therapy in MLL-AF9 leukemia
Benjamin Mizukawa, Junping Wei, Mahesh Shrestha, et al.
Cancer Cell
|
June 10, 2008
Microenvironment determines lineage fate in a human model of MLL-AF9 leukemia
Junping Wei, Mark Wunderlich, Catherine Fox, et al.
Vaccines
|
November 26, 2024
Vaccination Against Androgen Receptor Splice Variants to Immunologically Target Prostate Cancer
Robert D Marek, Selena Halabi, Mu-En Wang, et al.
Breast Cancer Research : BCR
|
August 11, 2018
Polyfunctional anti-human epidermal growth factor receptor 3 (anti-HER3) antibodies induced by HER3 vaccines have multiple mechanisms of antitumor activity against therapy resistant and triple negative breast cancers
Takuya Osada, Zachary C Hartman, Junping Wei, et al.
Oncoimmunology
|
July 7, 2017
Vaccination targeting human HER3 alters the phenotype of infiltrating T cells and responses to immune checkpoint inhibition
Takuya Osada, Michael A Morse, Amy Hobeika, et al.
Journal of Translational Medicine
|
February 14, 2012
Phase 1 clinical trial of HER2-specific immunotherapy with concomitant HER2 kinase inhibition [corrected]
Erika Hamilton, Kimberly Blackwell, Amy C Hobeika, et al.
Page
of 8